Posted by Michael Wonder on 29 Aug 2017
Fotivda (tivozanib) now licensed in the European Union for the first-line treatment of advanced renal cell carcinoma
28 August 2017 - EUSA Pharma today announced that the European Commission has licensed Fotivda for the management of adult patients with advanced renal cell carcinoma in the European Union plus Norway and Iceland.
Tivozanib is indicated for the first line treatment of adult patients with advanced renal cell carcinoma and for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced RCC.
Tivozanib is an oral, once-daily, potent selective vascular endothelial growth factor receptor tyrosine kinase inhibitors.
